Human papilloma virus treatment

Abstract

Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disclosed is a method of treating a human papilloma virus infection in a subject infected or suspected of being infected with a human papilloma virus of a first type by administering to the subject a composition containing (1) a heat shock protein or an antigenic fragment thereof, and (2) a protein of a human papilloma virus of a second type or an antigenic fragment thereof, where the first type and second type are different.

What is claimed is:  
     
         1 . A method of treating a wart in a subject, the method comprising 
 identifying a subject having or suspected of having a wart; and    administering to the subject a composition comprising a fusion protein comprising (1) a heat shock protein (hsp) or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus (HPV), or an antigenic fragment thereof, wherein the composition is administered in an amount sufficient to treat the wart.    
     
     
         2 . The method of  claim 1 , wherein the hsp is a mycobacterial hsp.  
     
     
         3 . The method of  claim 2 , wherein the mycobacterial hsp is a  Mycobacterium bovis  hsp.  
     
     
         4 . The method of  claim 3 , wherein the hsp is  Mycobacterium bovis  Hsp65.  
     
     
         5 . The method of  claim 1 , wherein the hsp is a member of the Hsp 60 or Hsp 70 family of proteins.  
     
     
         6 . The method of  claim 1 , wherein the HPV is a type 16 HPV.  
     
     
         7 . The method of  claim 1 , wherein the protein of the HPV is an E7 protein.  
     
     
         8 . The method of  claim 1 , wherein the composition contains about 50 to 5000 μg of the fusion protein.  
     
     
         9 . The method of  claim 8 , wherein the composition contains about 100 to 2000 μg of the fusion protein.  
     
     
         10 . The method of  claim 1 , wherein the composition is administered free of adjuvant.  
     
     
         11 . The method of  claim 1 , wherein the subject is a mammal.  
     
     
         12 . The method of  claim 11 , wherein the mammal is a human.  
     
     
         13 . The method of  claim 1 , wherein the fusion protein is administered in an amount sufficient to reduce the size of the wart.  
     
     
         14 . A method of treating, in a subject, a disease or condition associated with a human papilloma virus (HPV), the method comprising 
 administering to the subject a composition comprising a fusion protein comprising (1) an hsp, or an immunostimulatory fragment thereof, and (2) a protein of an HPV, or an antigenic fragment thereof, wherein the subject is infected with an HPV type that is different from the HPV type administered to the subject, the composition being administered in an amount sufficient to treat the disease or condition.    
     
     
         15 . The method of  claim 14 , wherein the hsp is a mycobacterial hsp.  
     
     
         16 . The method of  claim 15 , wherein the mycobacterial hsp is a  Mycobacterium bovis  hsp.  
     
     
         17 . The method of  claim 16 , wherein the hsp is  Mycobacterium bovis  Hsp65.  
     
     
         18 . The method of  claim 14 , wherein the hsp is a member of the Hsp 60 or Hsp 70 family of proteins.  
     
     
         19 . The method of  claim 14 , wherein the HPV type administered to the subject is type 16.  
     
     
         20 . The method of  claim 19 , wherein the subject has a disease or condition associated with an HPV of type 5, 6, 11, 18, 31, 33, 35, 45, 54, 60, or 70.  
     
     
         21 . The method of  claim 20 , wherein the subject has a disease or condition associated with an HPV of type 6, 11, 33, 45, or 70.  
     
     
         22 . The method of  claim 21 , wherein the subject has a disease or condition associated with an HPV of type 6 or 11.  
     
     
         23 . The method of  claim 14 , wherein the protein of the HPV is an E7 protein.  
     
     
         24 . The method of  claim 14 , wherein the composition contains about 50 to 5000 μg of the fusion protein.  
     
     
         25 . The method of  claim 24 , wherein the composition contains about 100 to 2000 μg of the fusion protein.  
     
     
         26 . The method of  claim 14 , wherein the composition is free of adjuvant.  
     
     
         27 . The method of  claim 14 , wherein the subject is a mammal.  
     
     
         28 . The method of  claim 27 , wherein the mammal is a human.  
     
     
         29 . The method of  claim 14 , wherein the subject is not identified as being infected with the type of HPV that is administered prior to administration of the composition.  
     
     
         30 . A method of treating a wart in a subject, the method comprising 
 identifying a subject having, or suspected of having, a wart;    administering to the subject a nucleic acid encoding a fusion polypeptide comprising (1) an hsp, or an immunostimulatory fragment thereof, and (2) a protein of an HPV or an antigenic fragment thereof; and    expressing the fusion polypeptide in the subject in an amount sufficient to treat the wart.    
     
     
         31 . The method of  claim 30 , wherein the nucleic acid is contained within a viral vector.  
     
     
         32 . A method of treating, in a subject, a disease or condition associated with an HPV infection, the method comprising: 
 administering to the subject a nucleic acid encoding a fusion protein comprising (1) an hsp, or an immunostimulatory fragment thereof, and (2) a protein of an HPV, wherein the subject is infected with an HPV type that is different from the HPV type administered to the subject; and    expressing the fusion protein in the subject in an amount sufficient to treat the disease or condition.    
     
     
         33 . The method of  claim 32 , wherein the nucleic acid is contained within a viral vector.  
     
     
         34 . The method of  claim 14 , wherein the disease or condition is anogenital warts, plantars warts, cervical cancer, cervical dysplasia, anal cancer, anal dysplasia, or recurrent respiratory papillomatosis.  
     
     
         35 . The method of  claim 32 , wherein the disease or condition is anogenital warts, plantars warts, cervical cancer, cervical dysplasia, anal cancer, anal dysplasia, or recurrent respiratory papillomatosis.